Literature DB >> 16837208

Commonly used mouse models of osteosarcoma.

Eugene T H Ek1, Crispin R Dass, Peter F M Choong.   

Abstract

Osteosarcoma is the commonest primary tumour of bone and the second highest cause of cancer-related death in the paediatric age group. Little is known of the aetiology of human osteosarcoma and lesser still of the various interactions that occur between host and tumour cells that govern growth and progression of osteosarcoma in vivo. Although numerous osteosarcoma cell lines have been established and characterized in vitro, some as far back as in the 1960s, there is a scarcity of reliable and reproducible in vivo animal models that mimics all aspects of the human condition at the temporal, physiological and histopathological level, hence, making the accurate testing of therapeutic strategies difficult. Given that osteosarcoma is a disease that affects young people and better disease management strategies are essential, development of a robust human osteosarcoma model is long overdue.

Entities:  

Mesh:

Year:  2006        PMID: 16837208     DOI: 10.1016/j.critrevonc.2006.03.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  35 in total

1.  Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases.

Authors:  Jun Yuan; Christian Ossendorf; Jan P Szatkowski; James T Bronk; Avudaiappan Maran; Michael Yaszemski; Mark E Bolander; Gobinda Sarkar; Bruno Fuchs
Journal:  Cancer Invest       Date:  2009-05       Impact factor: 2.176

2.  Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model.

Authors:  Yaojuan Lu; Steven Gitelis; Guanghua Lei; Ming Ding; Carl Maki; Ranim R Mira; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

3.  Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis.

Authors:  Guillermo Romero; W Bruce Sneddon; Yanmei Yang; David Wheeler; Harry C Blair; Peter A Friedman
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

4.  A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma.

Authors:  Crispin R Dass; Eugene T Ek; Karla G Contreras; Peter F Choong
Journal:  Clin Exp Metastasis       Date:  2006-12-23       Impact factor: 5.150

5.  Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.

Authors:  Zhenhua Zhou; Yan Li; Xu Yan; Xudong Wang; Cheng Yang; Haifeng Wei; Xinghai Yang; Jianru Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-27       Impact factor: 4.553

6.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

7.  NHERF1 regulates parathyroid hormone receptor desensitization: interference with beta-arrestin binding.

Authors:  Bin Wang; Yanmei Yang; Abdul B Abou-Samra; Peter A Friedman
Journal:  Mol Pharmacol       Date:  2009-02-02       Impact factor: 4.436

8.  Osteosarcoma: mouse models, cell of origin and cancer stem cell.

Authors:  Maria V Guijarro
Journal:  Postdoc J       Date:  2014-02

9.  Targeted deletion of Wwox reveals a tumor suppressor function.

Authors:  Rami I Aqeilan; Francesco Trapasso; Sadiq Hussain; Stefan Costinean; Dean Marshall; Yuri Pekarsky; John P Hagan; Nicola Zanesi; Mohamed Kaou; Gary S Stein; Jane B Lian; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

10.  Metastatic osteosarcoma gene expression differs in vitro and in vivo.

Authors:  Jennifer W Lisle; Joseph Y Choi; Jason A Horton; Matthew J Allen; Timothy A Damron
Journal:  Clin Orthop Relat Res       Date:  2008-05-31       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.